Abstract | The selective utilization of IRAK kinases, which are thought to be recruited to MyD88 to form the 'Myddosome', has been shown to differ substantially in mouse and human cells. This finding has important implications for the development of therapeutics for inflammatory and autoimmune disorders associated with Toll-like receptors. 
The myeloid differentiation primary response protein MyD88 (hereby referred to as MyD88) signalling pathway is central for the development of inflammation induced by nearly all Toll-like receptors (TLRs). However, analysis of these mechanisms is often guided by murine models, which may or may not coincide functionally with the mechanisms in humans. Sun et al. 1 performed a high-throughput RNA interference (RNAi)-based screen of human and mouse macrophage cell lines to identify species-specific differences in the relative importance of gene products that contribute to TLR signalling leading to TNF expression in humans or to Tnf expression and NFκB activation in mice. This work is a tour de force that resulted in the identification of a family of related proteins that differentially mediate TLRdependent, MyD88-dependent signalling in mouse and human cells. The researchers initially selected 126 inflammatory genes for screening, including representative genes that encode receptor-proximal signalling adaptors, and also signal transducers, negative regulators and transcription factors. The effect of RNAi-driven gene knockdown was greatest when the levels of proximal signalling molecules were downregulated.
Sun et al. 1 focused on species-specific differences in sensitivity to RNAi-driven silencing among the genes that encode IL-1 receptor-associated kinases (IRAKs). This family of related proteins have scaffolding and/or kinase activities and facilitate the formation of the 'Myddosome' , a very large multicomponent Another point of divergence between human and mouse cells was shown by immunoprecipitation experiments in which murine MyD88 interacted in a rapid and sustained manner with murine IRAK-4, whereas human MyD88-IRAK-4 interactions took longer to form and were more transient 1 . This observation implies that a difference in the manner in which IRAK-4 initially interacts with MyD88 exists between mice and humans, with either the structure of MyD88 or that of IRAK-4 making this initial interaction weaker in humans. We did a rudimentary comparison of the amino acid sequences of mouse and human MyD88 using the Basic Local Alignment Search Tool (BLAST) that shows the greatest differences in sequence are in the death domains of the proteins. These differences could explain the finding that the expression of murine IRAK-4 from a plasmid could not restore TLR signalling in human IRAK-4-deficient cells and vice versa. A more extensive analysis of differences in the sequences of human and mouse MyD88 and IRAK-4, confirmed by site-directed mutagenesis, would be required to investigate this hypothesis.
Studies from other research groups have revealed that murine IRAK-4 possesses both catalytic and scaffolding activities 2 . Sun et al. 1 also found that a mutant murine IRAK-4 in which kinase activity had been abolished could not reconstitute TLR signalling in murine IRAK-4-deficient macrophages, whereas a human IRAK-4 in which kinase activity had been similarly abolished was able to mediate TLR signalling in human IRAK-4-deficient macrophages. This observation implies that TLR signalling in mouse cells requires the catalytic and scaffolding functions of IRAK-4, whereas TLR signalling and its effects on gene structure that mediates MyD88-dependent signalling. The principal findings of the study suggest that IRAK-2 and IRAK-4, but not IRAK-1, are required for MyD88-dependent, TLRdriven signalling in the mouse RAW 264 cell line, whereas IRAK-1 is the predominant IRAK in this pathway in human THP-1 macrophages, with knockdown of IRAK-4 and IRAK-2 having smaller effects on signal transduction.
The Myddosome is thought to assemble in a hierarchical order, with MyD88 being recruited initially to TLRs via interactions between two Toll-IL-1 receptor/resistance (TIR) domains . Such mutations, and particularly those that generate stop codons within the kinase domain, might greatly reduce the expression of truncated IRAK-4 proteins in a patient's cells. The reduced expression of these proteins could account for the failure to mount an appropriate response to TLR2 and TLR4 stimulation that occurs in patients with IRAK-4 deficiency, and for the striking susceptibility of these patients to repeated infection with Gram-positive bacteria 5, 6 . However, other evidence suggests that IRAK-4 proteins with mutations within the kinase domain can be functional. In a study in which two different constructs expressing mutations in the catalytic domain of IRAK-4, which were found in a patient with a compound heterozygous genotype, were overexpressed in lipopolysaccharide (LPS)-responsive human cells, the mutated IRAK-4 proteins were detectable and behaved as dominant-negative inhibitors of MyD88-dependent signalling, presumably through their scaffolding regions 8 . The analysis by Sun et al. 1 was further extended to investigating the role of IRAK-1 and IRAK-2 in mouse and human cells. As previously reported 9 , Irak2 −/− murine macrophages were highly unresponsive to TLR2 ligands (the synthetic Pam3CSK4 agonist or peptidoglycan) or a TLR7 ligand (the synthetic R848 agonist), as measured by diminished induction of inflammatory genes compared with that in wild-type macrophages, whereas the responses of Irak1 −/− macrophages to signalling induced by these TLRs were minimally affected. Conversely, IRAK-2 had a limited role in human macrophages, whereas IRAK-1 was essential for TLR signalling 9 .
Although the study by Sun et al.
1 presents many provocative findings, its experimental design imposes some limitations on the interpretation of the results. First, the effect of the RNAi knockdown experiments on induction of gene expression was analysed only with regards to the human and mouse genes encoding TNF. This cytokine is a widely used readout for TLR signal transduction and an important inflammatory mediator, but many other such proteins exist. Unfortunately, the screen does not provide information about the behaviour of MyD88-independent TLR-responsive genes. Second, the TNF reporter gene was expressed from a lentiviral cassette inserted, presumably at random, into the genome. As such, the role of distal transcriptional enhancer elements and any differences in chromatin remodelling, which we now know are an important part of TLR responses, are not possible to analyse. A final limitation of the RNAi screening approach concerns its failure to identify roles for negative regulators of TLR responses. Silencing RNAs directed against several known negative regulators of these responses (IRAK-3, TNFAIP3, CYLD, etc.) were included in the initial screen, but substantial increases in the expression of the TNF reporter were not observed upon knockdown of these negative regulators. This lack of effect might result from the time points that were chosen for analysing the responses to RNAi in this screen, although this possibility would need to be investigated in further studies.
In conclusion, the work of Sun et al. 1 suggests that potentially important caveats exist when translating structure-function relationships in TLR signalling from animal models to humans. The difficulties encountered in previous attempts to devise small-molecule inhibitors targeting IRAKs for the treatment of human inflammatory disorders 10 highlight the need to take these caveats into account.
